Search PubMed⌕ Search

PubMed · 10421727

Polyacrylamide at Solid/Liquid Interfaces.

Abstract

In the literature, the term polyacrylamide refers to neutral, hydrolyzed, and chemically modified polyacrylamide and in this sense polyacrylic acid may likewise be considered to consist of hydrolyzed acrylamide groups. These hydrosoluble polymers are employed in wide range of applications where the polymer characteristics at solid-liquid interfaces play an important role. The interaction with solid adsorbents is very complex since electrostatic, hydration, van der Waals, and other forces operate simultaneously. As in most applications the polyacrylamide is brought into contact with oxides, clays or soils, synthetic alumino-silicates, and aluminum oxide may be used as model adsorbents. Thus, with reference to the two systems polyacrylamide/alumino-silicate and polyacrylamide/aluminum oxide, the author attempts to define some of the interfacial processes affecting the adsorbed macromolecules and to describe certain interfacial characteristics of these complex systems. The main results are as follows. -Neutral polyacrylamide. Hydrogen bonding between acrylamide and neutral aluminol groups is responsible for adsorption and the amount of polymer adsorbed parallels the surface density of aluminol sites. At ambient temperature, the kinetics of layer formation is governed initially by the random deposition of solution macromolecules and finally by tunneling. Thermodynamic and kinetic considerations lead to a model where the majority of the adsorbed macromolecule share identical dynamic characteristics under equilibrium conditions. Departure from equilibrium induced by changing the polymer concentration in the supernatant phase greatly modifies the dynamic features of the adsorbed macromolecules. -Hydrolyzed polyacrylamide. Charge-charge interactions superimpose on the persistent effects of hydrogen bonding to alter the amount of polymer adsorbed and the adsorption kinetics. The strong affinity of hydrolyzed polyacrylamide for positively charged surfaces induces interfacial spreading of the adsorbed macromolecules and in some instances desorption of part of this population (overshoots). -Complexed polyacrylamide. The presence of positively charged, negatively charged, and neutral chain segments confers amphoteric character on the polymer chain. Strongly complexed polymers display fast adsorption, while initially weakly complexed polymers show delayed adsorption. In addition, under certain circumstances, the presence of hydrophobic microdomains confers an amphiphilic character on the macromolecules, which profoundly modifies the nature of the interaction forces. The specific interaction typical of neutral polyacrylamide progressively disappears with increasing hydrolysis until for polyacrylic acid the surface coverage corresponds to nonselective interfacial deposition. Extremely slow displacement of hydrophilic and hydrophobic groups are found to occur within the adsorbed layer. Despite the promising use of macromolecules in environmental strategies, a consideration of the complexity of the underlying interfacial phenomena points to the difficulties which may arise at short or long terms in such applications. Copyright 1999 Academic Press.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E Pefferkorn. 1999-08-15. Polyacrylamide at Solid/Liquid Interfaces.. https://doi.org/10.1006/jcis.1999.6312

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗